Streetbeat News

Products Services

JSDA

Jones Soda Co. is launching its 'Stoner October' California 2023 tour events, visiting over 25 top cannabis dispensaries throughout California. The company's Mary Jones brand, launched in 2022, can now be found in more than 350 dispensaries across California and has expanded to multiple cannabis-legal states. The brand features iconic flavors adapted for cannabis, available in 10MG and 100MG THC. Jones Soda's shares traded 1.6304% higher at $0.1870 per share at the market close on Tuesday.

Portfolio Pulse from Jelena Martinovic

October 11, 2023 | 1:04 pm

AGRI

AgriFORCE Growing Systems Ltd. (NASDAQ:AGRI) and its partners Desico and Radical Clean Solutions Ltd will be showcasing their AgriFORCE/RCS Hydroxyl Devices at EXPO Guanajuato 2023. The devices, which have been selected as one of the top 20 new innovations at the EXPO, use hydroxyls to eliminate pathogens and VOCs in the air and on surfaces, providing continuous air and surface pathogen elimination for greenhouses, indoor farms, and processing facilities.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 1:03 pm

SINT

SINTX Technologies has been awarded a Phase II grant of $1,972,826 by the National Institutes of Health (NIH) to develop a 3D printed composite silicon nitride – polyetheretherketone (SN-PEEK) spinal implant. This is the fourth NIH grant awarded to SINTX. The company will collaborate with the University of Pennsylvania School of Veterinary Medicine over the next 24 months to execute this project. The NIH grant will support resourcing and acquisition of materials as well as testing and trials at SINTX and Penn Vet.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 1:02 pm

LXRX

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced that findings from two studies on the cost-effectiveness and budget impact of INPEFA, a drug recently approved by the FDA for heart failure treatment, will be presented at the Academy of Managed Care Pharmacy Nexus 2023 National Meeting. The company believes that the cost-effectiveness analysis and budget impact model for INPEFA will be crucial in driving decisions for formulary inclusion of this innovation.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 1:01 pm

BCS

BLK

GS

JPM

JPMorgan Chase & Co. has initiated its first collateral settlement using blockchain technology. The bank's Tokenized Collateral Network (TCN) facilitated BlackRock Inc. in converting shares from one of its money market funds into digital tokens. These tokens were then transferred to Barclays Plc as collateral for an over-the-counter derivatives deal. JPMorgan's Onyx Digital Assets network ensures almost immediate collateral movement, in contrast to traditional methods that could take a day. Other financial giants, including Goldman Sachs Group Inc., are also venturing into blockchain and digital assets.

Portfolio Pulse from Murtuza Merchant

October 11, 2023 | 1:01 pm

CNSP

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) has enrolled 229 of the expected 243 patients in its ongoing study evaluating Berubicin for the treatment of recurrent Glioblastoma Multiforme (GBM), an aggressive form of brain cancer. The company is on track to complete enrollment by year-end and expects to report interim analysis results later this quarter. The FDA has granted CNS Pharmaceuticals Fast Track Designation for Berubicin, which expedites the development and review process.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 12:48 pm

VFS

VinFast, a Vietnamese automaker, anticipates an increase in its short-term costs due to battery research and development (R&D) and factory operations.

Portfolio Pulse from Bill Haddad

October 11, 2023 | 12:48 pm

CDT

Conduit Pharmaceuticals Inc. (NASDAQ:CDT) has announced a partnership with ClinConnect to conduct a cocrystal development program for its AZD1656 compound, a molecule with potential treatment applications in various autoimmune disorders. The program aims to improve the solubility, stability, and bioavailability of AZD1656. Conduit, which went public in September 2023, acquires assets that have undergone some pre-clinical and clinical testing and works to accelerate them through Phase II trials.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 12:45 pm

AAPL

A survey by investment firm Piper Sandler reveals that Apple Inc.'s iPhones continue to be popular among American teenagers, with 87% of them owning an iPhone and 88% expecting it to be their next phone. The Apple Watch has also gained traction among teenagers, with 34% owning one. However, enthusiasm for purchasing a new Apple Watch in the next six months has dipped to 10%, down from 16% the previous year.

Portfolio Pulse from Rounak Jain

October 11, 2023 | 12:43 pm

NVO

PHIO

TPST

Tempest Therapeutics (TPST) released new data showing superiority of TPST-1120 across multiple study endpoints, causing a 440% increase in its stock. Phio Pharmaceuticals (PHIO) presented new data for targeting BRD4 with its INTASYL™ Compound PH-894, leading to a 77% increase in its stock. Novo Nordisk (NVO) shares rose by 5.3% after the independent Data Monitoring Committee recommended to stop semaglutide FLOW kidney trial due to signs of early efficacy.

Portfolio Pulse from ryanfaloona@benzinga.com

October 11, 2023 | 12:42 pm